These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Genomic analysis reveals different mechanisms of fusidic acid resistance in Staphylococcus aureus from Danish atopic dermatitis patients. Edslev SM, Clausen ML, Agner T, Stegger M, Andersen PS. J Antimicrob Chemother; 2018 Apr 01; 73(4):856-861. PubMed ID: 29253168 [Abstract] [Full Text] [Related]
6. Antimicrobial resistance of Staphylococcus aureus isolated from skin infections and its implications in various clinical conditions in Korea. Baek YS, Jeon J, Ahn JW, Song HJ. Int J Dermatol; 2016 Apr 01; 55(4):e191-7. PubMed ID: 26892888 [Abstract] [Full Text] [Related]
7. Susceptibility of skin and soft-tissue isolates of Staphylococcus aureus and Streptococcus pyogenes to topical antibiotics: indications of clonal spread of fusidic acid-resistant Staphylococcus aureus. Afset JE, Maeland JA. Scand J Infect Dis; 2003 Apr 01; 35(2):84-9. PubMed ID: 12693555 [Abstract] [Full Text] [Related]
8. Emerging multidrug resistance in community-associated Staphylococcus aureus involved in skin and soft tissue infections and nasal colonization. Lee GC, Dallas SD, Wang Y, Olsen RJ, Lawson KA, Wilson J, Frei CR. J Antimicrob Chemother; 2017 Sep 01; 72(9):2461-2468. PubMed ID: 28859442 [Abstract] [Full Text] [Related]
9. Susceptibility of Staphylococcus aureus to topical agents in the United States: a sentinel study. Biedenbach DJ, Bouchillon SK, Johnson SA, Hoban DJ, Hackel M. Clin Ther; 2014 Jun 01; 36(6):953-60. PubMed ID: 24835558 [Abstract] [Full Text] [Related]
14. Repurposing auranofin for the treatment of cutaneous staphylococcal infections. Thangamani S, Mohammad H, Abushahba MF, Sobreira TJ, Seleem MN. Int J Antimicrob Agents; 2016 Mar 01; 47(3):195-201. PubMed ID: 26895605 [Abstract] [Full Text] [Related]
15. Susceptibility to and resistance determinants of fusidic acid in Staphylococcus aureus isolated from Chinese children with skin and soft tissue infections. Liu Y, Geng W, Yang Y, Wang C, Zheng Y, Shang Y, Wu D, Li X, Wang L, Yu S, Yao K, Shen X. FEMS Immunol Med Microbiol; 2012 Mar 01; 64(2):212-8. PubMed ID: 22066960 [Abstract] [Full Text] [Related]
16. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale. Williamson DA, Monecke S, Heffernan H, Ritchie SR, Roberts SA, Upton A, Thomas MG, Fraser JD. Clin Infect Dis; 2014 Nov 15; 59(10):1451-4. PubMed ID: 25139961 [Abstract] [Full Text] [Related]
17. Mupirocin: a new topical antibiotic. Leyden JJ. J Am Acad Dermatol; 1990 May 15; 22(5 Pt 1):879-83. PubMed ID: 2112165 [Abstract] [Full Text] [Related]
19. Susceptibility in vitro of canine methicillin-resistant and -susceptible staphylococcal isolates to fusidic acid, chlorhexidine and miconazole: opportunities for topical therapy of canine superficial pyoderma. Clark SM, Loeffler A, Bond R. J Antimicrob Chemother; 2015 Jul 15; 70(7):2048-52. PubMed ID: 25749003 [Abstract] [Full Text] [Related]
20. Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections. Hurdle JG, O'Neill AJ, Chopra I. J Antimicrob Chemother; 2004 Aug 15; 54(2):549-52. PubMed ID: 15243028 [Abstract] [Full Text] [Related] Page: [Next] [New Search]